NanoPhoria Bioscience is emerging as one of Italy’s most ambitious biotech companies, with a clear focus on transforming how serious heart conditions are treated. The company is developing a new class of inhalable cardiovascular therapies based on a proprietary non-viral, nano-in-micro delivery platform designed specifically for biologics. At the core of this approach is an inorganic calcium-phosphate nanoparticle that enables precise, tissue-directed delivery to the heart—an area where traditional systemic treatments often fall short.
This innovative strategy is aimed at tackling chronic and life-threatening cardiac diseases, particularly heart failure with reduced ejection fraction (HFrEF), by directly improving cardiac function while potentially reducing off-target effects. NanoPhoria’s lead candidate, NP-MP1, is being advanced as a first-in-class therapy that leverages inhalation as a patient-friendly route to reach cardiac tissue efficiently.
The company’s momentum was strongly validated by the close of an €83.5 million Series A round, one of the largest ever raised by an Italian biotech at this stage. The financing reflects exceptional investor confidence in NanoPhoria’s technology and vision, and it will be used to accelerate clinical development and bring NP-MP1 closer to patients. More broadly, the round positions NanoPhoria as a standout example of Europe’s growing capability to generate globally competitive biotech innovation, particularly in the high-unmet-need area of cardiovascular disease.
Contact us: santarovich@gmail.com
Support us: https://paypal.me/OlgaSantarovich